Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
The following is a brief description of each matter voted upon at
the Sarepta Therapeutics, Inc. (the Company) Annual
Meeting held on June6, 2017 (the Annual Meeting) and the
number of votes cast for, against or withheld (or, with respect
to the advisory vote on the frequency of future advisory votes on
executive compensation, the number of votes cast for one year,
two years or three years or withheld), as well as the number of
abstentions and broker non-votes, as to each such
matter. As of the record date for the Annual Meeting, April11,
2017, there were 54,940,604 shares of common stock issued and
outstanding. There were 44,822,091 shares of common stock present
and entitled to vote at the Annual Meeting in person or by proxy,
which represented 81.58% of the voting power of the shares of
common stock entitled to vote at the Annual Meeting, and which
constituted a quorum for the transaction of business.
The proposals
voted upon and voting results for these proposals at the Annual
Meeting were as follows:
Proposal 1:
Election of Group II Directors
|
Name of Nominee |
For | Against | Abstain | BrokerNon- Votes | ||||||||||||
|
Richard J. Barry |
27,195,571 | 409,914 | 783,761 | 16,432,845 | ||||||||||||
|
M. Kathleen Behrens, Ph.D. |
27,330,123 | 267,547 | 791,576 | 16,432,845 | ||||||||||||
|
Claude Nicaise, M.D. |
27,370,781 | 234,551 | 783,914 | 16,432,845 |
to the foregoing
votes, the Director nominees listed above were elected to serve
as a Group II Directors on the Companys Board of Directors to
hold office until the Companys 2019 annual meeting of
stockholders, or until his or her successor is earlier elected.
There were no additional director nominations brought before the
meeting.
Proposal 2:
Advisory Vote on 2016 Named Executive Officer
Compensation
|
For |
Against |
Abstain |
Broker Non-Votes |
|||
|
27,952,585 |
291,029 | 145,632 | 16,432,845 |
to the foregoing
votes, the 2016 executive compensation was approved on an
advisory basis.
Proposal 3:
Advisory Vote on whether an Advisory Vote on Executive
Compensation Should Be Held Every One, Two or Three
years
|
One Year |
Two Years |
Three Years |
Abstain |
Broker Non-Votes |
||||
|
25,067,912 |
168,815 | 3,094,877 | 57,642 | 16,432,845 |
to the foregoing
votes, the frequency of one year for advisory vote on executive
compensation was approved on an advisory basis. In light of such
vote, the Companys Board of Directors has determined that it will
include annually in the proxy materials an advisory vote on the
compensation of its named executive officers until the next vote
on the frequency of shareholder votes on the compensation of
named executive officers is held.
Proposal 4:
Ratification of KPMG as the Companys Independent Registered
Public Accounting Firm
|
For |
Against |
Abstain |
||
|
44,541,022 |
183,511 | 97,558 |
to the foregoing
votes, the selection of KPMG LLP as the Companys independent
registered public accounting firm for the year ending December31,
2017 was ratified and approved.
| Item8.01. | Other Events. |
On May19, 2017
(the Effective Date), Mr.Alexander Bo Cumbo was promoted
to Senior Vice President, Chief Commercial Officer. In connection
with his promotion, Mr.Cumbos annual salary was increased to
$380,000 effective as of the Effective Date, and he was granted
an option to purchase 40,000 shares of the Company common stock
on the Effective Date (the Option). 25% of the Option
vests and is exercisable on May19, 2018, and 1/48th of the total Option will vest
and become exercisable ratably in monthly installments over the
next three years, such that the Option will be fully vested and
exercisable on May19, 2021.
About Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.
